Group 1 - The core viewpoint of the article highlights the performance and valuation of Kangdelai, a company in the medical device industry, which has a current PE ratio of 15.18, significantly lower than the industry average of 49.64 [1][2] - As of March 31, 2025, Kangdelai has 25,817 shareholders, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, sales, and service of medical devices, including various types of medical needles and infusion devices [1] Group 2 - In the latest quarterly report for Q1 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, with a slight increase of 0.28% [1] - The gross profit margin for the company stands at 32.02% [1] - Kangdelai ranks 35th in terms of PE ratio within its industry, which has a median PE of 36.36 [2]

Distribution Plan - The profit distribution plan was approved at the company's annual shareholders' meeting on May 12, 2025 [1] - The distribution is based on the total share capital of 436,790,880 shares, with a cash dividend of 0.15 yuan per share (before tax), totaling 65,518,632.00 yuan [1][3] Distribution Implementation - The cash dividends will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch after the market closes on the record date [1] - Shareholders who have completed designated transactions can receive their cash dividends on the distribution date at their designated securities business department [1] Taxation Information - For individual shareholders, dividends are subject to different tax treatments based on the holding period of the shares, with specific rates outlined for various holding periods [4] - QFII (Qualified Foreign Institutional Investors) are subject to a 10% corporate income tax on dividends received from domestic sources, which will be withheld by the distributing company [5] - For Hong Kong investors, a 10% withholding tax will apply until the necessary identification and holding period data can be provided [6] Contact Information - For inquiries regarding the equity distribution matters, shareholders can contact the board office of Shanghai Kangdelai Enterprise Development Group Co., Ltd. at 021-69113502 [7]

上海康德莱企业发展集团股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 证券代码：603987 证券简称：康德莱 公告编号：2025-016 A 股每股现金红利0.15元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/6/5 | － | 2025/6/6 | 2025/6/6 | 差异化分红送转：否 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 12 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本436,790,880股为基数，每股派发现 金红利0.15元（含税），共计派发现金红利6 ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Kangdai, a company in the medical device industry, which is currently facing challenges with a lower-than-average PE ratio compared to its peers [1][2] - As of May 22, Kangdai's closing price was 7.35 yuan, with a rolling PE ratio of 14.90 times and a total market capitalization of 3.21 billion yuan [1] - The average PE ratio for the medical device industry is 48.71 times, with a median of 35.37 times, placing Kangdai at the 34th position within the industry [1][2] Group 2 - As of the first quarter of 2025, seven institutions hold shares in Kangdai, with a total of 197.34 million shares valued at 1.446 billion yuan [1] - Kangdai's main business includes the research, production, sales, and service of medical devices such as puncture needles and infusion devices, with a diverse product range [1] - The latest financial report for the first quarter of 2025 shows Kangdai achieved a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, a year-on-year increase of 0.28%, with a gross profit margin of 32.02% [1]

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kangdelai, a company in the medical device industry, which has a current PE ratio of 15.12, significantly lower than the industry average of 49.51 [1][2] - As of March 31, 2025, Kangdelai has 25,817 shareholders, a decrease of 822 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in the research, production, and sales of medical devices, including puncture needles and infusion devices, with its R&D centers recognized at both municipal and provincial levels [1] Group 2 - In the latest quarterly report for Q1 2025, Kangdelai reported a revenue of 548 million yuan, a year-on-year decrease of 3.82%, and a net profit of 60.70 million yuan, with a slight increase of 0.28% [1] - The gross profit margin for the company stands at 32.02%, indicating its profitability in the current market conditions [1] - The company ranks 35th in terms of PE ratio within its industry, reflecting its relative valuation compared to peers [2]

证券代码：603987 证券简称：康德莱 公告编号：2025-015 上海康德莱企业发展集团股份有限公司 2024年年度股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (四) 表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况 等。 本次股东会由副董事长陈红琴女士主持，公司部分董事、全体监事、部分高 级管理人员及见证律师等相关人员出席会议。会议程序符合《公司法》等相关法 律法规、部门规章、规范性文件和《公司章程》的规定。 (一) 股东会召开的时间：2025 年 5 月 12 日 (二) 股东会召开的地点：上海市嘉定区高潮路 658 号会议室 (五) 公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席6人，董事长张宪淼先生，董事、副总经理章增华先 生，董事、副总经理张勇先生因工作原因无法出席会议； 2、公司在任监事 3 人，出席 3 人； 3、董事会秘书顾佳俊女士及财务总监沈晓如先生出席了本次会议。 二、 议案审议情况 ...

德恒上海律师事务所 关于 上海康德莱企业发展集团股份有限公司 2024 年年度股东会之 见证意见 上海市东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-55989888/55989666 传真：021-5598 9898 邮编：200080 德恒上海律师事务所 关于上海康德莱企业发展集团股份有限公司 2024 年年度股东会之见证意见 德恒上海律师事务所 关于上海康德莱企业发展集团股份有限公司 2024 年年度股东会之 见证意见 德恒 02G20170018-00033 号 致：上海康德莱企业发展集团股份有限公司 德恒上海律师事务所接受上海康德莱企业发展集团股份有限公司（以下或称 "公司"）的委托，指派本所见证律师对公司于 2025 年 5 月 12 日 9:30 召开的 2024 年年度股东会（以下简称"本次股东会"）进行见证并出具本见证意见。 本所见证律师依据本见证意见出具日前已经发生或存在的事实和《中华人民 共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"） 等现行有效的法律、法规和规范性文 ...

证券代码：603987 证券简称：康德莱 公告编号：2025-014 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 上海康德莱企业发展集团股份有限公司 关于参加 2025 年上海辖区上市公司年报集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 5 月 15 日（星期四）15:00-16:30 总经理：张维鑫 董事会秘书：顾佳俊 财务总监：沈晓如 独立董事：邵军 投资者可于 2025 年 05 月 08 日（星期四）至 05 月 14 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dm@kdlchina.net 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 上海康德莱企业发展集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 19 日发布公司 2024 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603987 证券简称：康德莱 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 □适用 √不适用 ...

Financial Data and Indicators - The basic earnings per share (EPS) for Q1 2025 remained unchanged at 0.1400 CNY compared to Q1 2024, but decreased from 0.1900 CNY in Q1 2023 [1] - The net asset per share increased by 5.87% to 5.95 CNY from 5.62 CNY in Q1 2024, and from 5.26 CNY in Q1 2023 [1] - The retained earnings per share rose by 10.71% to 3.41 CNY compared to 3.08 CNY in Q1 2024, and increased from 2.86 CNY in Q1 2023 [1] - The operating revenue decreased by 3.86% to 5.48 billion CNY from 5.7 billion CNY in Q1 2024, and significantly decreased from 6.87 billion CNY in Q1 2023 [1] - The net profit remained stable at 0.61 billion CNY compared to Q1 2024, but decreased from 0.85 billion CNY in Q1 2023 [1] - The return on equity (ROE) decreased by 5.22% to 2.36% from 2.49% in Q1 2024, and decreased from 3.75% in Q1 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 20,244.86 million shares, accounting for 46.35% of the circulating shares, with a decrease of 203.63 million shares compared to the previous period [1] - Shanghai Kangdelai Holding Group Co., Ltd. remains the largest shareholder with 17,286.82 million shares, representing 39.58% of the total share capital, unchanged from the previous period [2] - New entrants to the top ten shareholders include China Bank's investment fund with 578.47 million shares (1.32%) and China Construction Bank's investment fund with 421.00 million shares (0.96%) [2] - Notable exits from the top ten shareholders include the招商量化精选股票A fund, which exited with 531.47 million shares (1.21%) [2] Dividend Distribution - The company has announced that there will be no distribution or transfer of dividends this time [3]